ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/
SC 13D, 1998-11-09
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: WHITEFORD PARTNERS L P, 10-Q, 1998-11-09
Next: PEOPLES TELEPHONE COMPANY INC, 10-Q/A, 1998-11-09



<PAGE>
                                       
                      SECURITIES AND EXCHANGE COMMISSION
                                       
                           Washington, D.C. 20549
                                       
                                SCHEDULE 13D
                                       
                 Under the Securities Exchange Act of 1934
                             (Amendment No. 1)
                                       

                    ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
- -------------------------------------------------------------------------------
                              (Name of Issuer)

                       COMMON STOCK, PAR VALUE $.01
- -------------------------------------------------------------------------------
                       (Title of Class of Securities)
                                       
                                   042698209             
- -------------------------------------------------------------------------------
                                (CUSIP Number)
                                       
  RUSSELL C. CHAMBERS, 772 POTATO PATCH, VAIL, COLORADO 81657 (512) 343-6912
- -------------------------------------------------------------------------------
     (Name, Address and Telephone Number of Person Authorized to Receive 
                         Notices and Communications)
                                       
                               OCTOBER 30, 1998 
- -------------------------------------------------------------------------------
              (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to 
report the acquisition that is the subject of this Schedule 13D, and is 
filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 
240.13d-1(g), check the following box. _____

NOTE: Schedules filed in paper format shall include a signed original and 
five copies of the schedule, including all exhibits.  See Section 
240.13d-7(b) for the other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting 
person's initial filing on this form with respect to the subject class of 
securities, and for any subsequent amendment containing information which 
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be 
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange 
Act of 1934 ("Act") or otherwise subject to the liabilities of that section 
of the Act but shall be subject to all other provisions of the Act (however, 
see Notes).
                                       
                                  Page 1 of 5

<PAGE>

<TABLE>
<CAPTION>
<S>  <C>

1)   Names of Reporting Persons I.R.S. Identification Nos. of Above Persons 
     (entities only) 

     Russell C. Chambers
- --------------------------------------------------------------------------------------------
2)   Check the Appropriate Box if a Member of a Group (See Instructions)

       (a) 
           ---------------------------------------------------------------------------------
       (b) 
           ---------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------
     3)  SEC Use Only
                      ----------------------------------------------------------------------
- --------------------------------------------------------------------------------------------
     4)   Source of Funds (See Instructions)    PF
- --------------------------------------------------------------------------------------------
     5)   Check if Disclosure of Legal Proceedings is Required Pursuant to 
          Item 2(d) or 2(e)
                            ----------------------------------------------------------------
- --------------------------------------------------------------------------------------------
     6)   Citizenship or Place of Organization    U.S.
- --------------------------------------------------------------------------------------------

    Number of       7)  Sole Voting Power   359,465 Shares Common Stock, $.01 Par Value
    Shares bene-    ------------------------------------------------------------------------
    ficially        8)  Shared Voting Power   N/A
    owned by each   ------------------------------------------------------------------------
    reporting       9)  Sole Dispositive Power 359,465 Shares Common Stock, $.01 Par Value
    Person with     ------------------------------------------------------------------------
                    10) Shared Dispositive Power   N/A
                    ------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------
     11)  Aggregate Amount Beneficially Owned by Each Reporting Person 
          359,465 Shares Common Stock, $.01 Par Value
- --------------------------------------------------------------------------------------------
     12)  Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See 
          Instructions)
                      ----------------------------------------------------------------------
- --------------------------------------------------------------------------------------------
     13)  Percent of Class Represented by Amount in Row (11)   10.1%
- --------------------------------------------------------------------------------------------
     14)  Type of Reporting Person (See Instructions)   IN
- --------------------------------------------------------------------------------------------
</TABLE>
                                  Page 2 of 5
<PAGE>

CUSIP No. 042698209                                               Page 3 of 5

     ITEM 1.   SECURITY AND ISSUER

     This statement relates to the $.01 Par Value Common Stock ("Common 
Stock") of Arrhythmia Research Technology, Inc. ("ART"), the principal 
executive offices of which are located at 5910 Courtyard Drive, Suite 300, 
Austin, Texas 78731.

     ITEM 2.   IDENTITY AND BACKGROUND

               (a)  Russell C. Chambers, MD

               (b)  Dr. Chambers' business address is 772 Potato Patch, Vail,
                    Colorado 81657.

               (c)  Dr. Chambers' principal occupation is overseeing his
                    personal investments.

               (d)  Dr. Chambers has not been convicted in a criminal proceeding
                    (excluding traffic violations or similar misdemeanors)
                    during the last five years.

               (e)  Dr. Chambers has not been a party to a civil proceeding of a
                    judicial or administrative body of competent jurisdiction
                    the result of which was a judgment, decree or final order
                    enjoining future violations of, or prohibiting or mandating
                    activities subject to federal or state securities laws or
                    finding any violation with respect to such laws during the
                    last five years.

               (f)  Dr. Chambers is a citizen of the United States.

     ITEM 3.   SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

     The Common Stock of ART has been purchased for an aggregate cash
consideration of $50,000.00 utilizing personal funds.

     ITEM 4.   PURPOSE OF TRANSACTION

     Dr. Chambers has purchased and sold the Common Stock of ART for investment
purposes.

<PAGE>

CUSIP No. 042698209                                               Page 4 of 5


     ITEM 5.   INTEREST IN SECURITIES OF THE ISSUER

               (a)  The aggregate number of shares of Common Stock of ART
                    beneficially owned by Dr. Chambers and the percentage which
                    those shares are of the outstanding Common Stock of ART are
                    as follows:

                Russell C. Chambers    359,465 shares    10.1 %

                (b) Dr. Chambers has the sole power to vote and the sole power 
                    to dispose or direct the disposition of all of the shares 
                    of Common Stock listed in subpart (a) of this Item.

                (c) The following transactions in the Common Stock of ART were 
                    effected by Dr. Chambers within the last sixty days:

<TABLE>
<CAPTION>
DATE           AMOUNT OF SECURITIES     PRICE PER SHARE     WHERE AND HOW EFFECTED
- ----           --------------------     ---------------     ----------------------
<S>            <C>                      <C>                 <C>
10/01/98        1,500 Shares            $1                  Open Market

10/06/98        5,000 Shares            $1-1/8              Open Market

10/08/98        5,000 Shares            $1-1/8              Open Market

10/15/98          500 Shares            $1-1/8              Open Market

10/19/98          100 Shares            $1-1/8              Open Market

10/20/98        4,400 Shares            $1-1/8              Open Market

10/21/9        10,000 Shares            $1-1/8              Open Market

10/22/98        5,000 Shares            $1-1/8              Open Market

10/30/98        3,500 Shares            $1                  Open Market

10/30/98       10,000 Shares            $1-1/8              Open Market
</TABLE>


     ITEM 6.   CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO  SECURITIES OF THE ISSUER

     Dr. Chambers does not have any contracts, arrangements, understandings, or
relationships (legal or otherwise) with any persons with respect to any
securities of ART, including but not limited to transfer or voting of any
securities of ART; finders fees; joint ventures; loan or option arrangements;
puts or calls; guarantees of profits; divisions of profits or losses; or the
giving or withholding of proxies.

<PAGE>

CUSIP No. 042698209                                               Page 5 of 5


     ITEM 7.   MATERIAL TO BE FILED AS EXHIBITS

     Not applicable.


     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

     Date:  November 6, 1998



                                        SIGNATURE  /s/ Russell C. Chambers 
                                                   ---------------------------
                                        NAME/TITLE:  Russell C. Chambers





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission